You keep insisting on comparing apples and oranges. You are wallowing in the wrong paradigm.
It is not about the size of the trial or the relationship between the phase 2 and 3 outcomes of a totally different drug. It is entirely about how the DXB-200 molecule performs in the Phase 3. If it achieves the trial endpoints, then accelerated approval will be a given. If it doesn't, like Travere, it will not get the approval. Simple.
I would think that most here suspect why you lack even-handedness and are trying so persistently to sew doubt about this trial. It's not altruism.
You keep insisting on comparing apples and oranges. You are...
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 47.5¢ | 45.5¢ | $934.4K | 2.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 548864 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 35747 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |